In this USH talk, Hester van Diepen provides an overview of the Usher development program at ProQR Therapeutics as an approach for possible future treatment of USH2A-associated retinitis pigmentosa.

Speaker Bio: Dr. Hester van Diepen currently leads the Usher syndrome development program at ProQR Therapeutics. ProQR Therapeutics is a young biotech company based in Leiden in the Netherlands focusing on the development of RNA therapies for rare genetic diseases. Hester joined ProQR in 2015 after obtaining her PhD in Ophthalmology and Neurophysiology at the Leiden University Medical Center. Since joining ProQR she entirely focuses on the Usher development programs to develop an RNA therapy as a treatment for retinitis pigmentosa caused by mutations in the USH2A gene.